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Introduction: Ductal Carcinoma In Situ (DCIS) is a heterogeneous, pre-malignant disease accounting for
15e20% of all new breast cancers. If appropriately managed, DCIS has a small chance of impacting on
patient life expectancy. Despite the possibility of a further recurrence or of a development in an invasive
form, we are unable to select treatment of choice especially in the elderly. In particularly we risk an
overtreatment of women at low risk of progression to invasive breast cancer. The aim of this study was to
retrospectively evaluate the outcome of elderly patients affected by DCIS not undergoing Radiation
Therapy (RT) after Breast Conserving Surgery (BCS). Material and methods: We reviewed our pro-
spectively-maintained database from 1998 to 2013, selecting all women over 65 years old diagnosed
with DCIS who did not receive RT for personal choice. We considered two groups, according to the risk of
local recurrence (Low Risk (Group 1) vs. High Risk (Group 2)). Results: We identiﬁed 44 cases of DCIS
treated with surgery alone or with surgery followed by adjuvant tamoxifen. 24 patients presented low
risk of local recurrence (Group 1) and 20 had characteristics associated to high risk of local recurrence
(Group 2). At a median follow-up of 66.3 months, no local recurrences have been described in group 1. No
patients presented distant metastases, while 4 patients died for other causes. At a median follow-up of 72
months we observed 5 local recurrences in the second group (p < 0.05). Conclusion: Our results suggest
that radiation therapy can be safely avoided in a selected group of elderly patients affected by DCIS.
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Ductal Carcinoma In Situ (DCIS) is an early form of breast cancer.
It is deﬁned by the World Health Organisation (WHO) as a
neoplastic intraductal lesion characterized by increased epithelial
proliferation, subtle to marked cellular atypia and an inherent but
not necessarily obligate tendency for progression to invasive breast
cancer [1]. Thewidespread adoption of screeningmammography in
the latest decades has led to a signiﬁcant increase in the incidence
of DCIS that nowadays accounts for about 15e20% of all newly
diagnosed cases of breast cancer [2e5]. Main goals of DCIS treat-
ment are maximizing breast conservation, optimizing cosmesis,.
Fig. 1. Risk of local recurrence in the ﬁrst group (blue line) compared with the second
group (green line). (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
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affected by DCIS have two surgical options: simple mastectomy
mainly used for extensive DCIS or Breast Conserving Surgery (BCS).
The latter, alongwith thewidespread use of oncoplastic techniques,
is nowadays considered the procedure of choice and it is followed
by Radiation Therapy (RT). RT after BCS has been proved to reduce
the rate of both in situ and invasive local recurrence [6e11];
however this reduction has not translated into a survival beneﬁt
and proponents of excision alone, in selected cases, have raised
[12e17]. First attempts to select low-risk patients who might not
beneﬁt from RT have been proposed by Silverstein and colleagues,
with the application of the Van Nuys Prognostic Index (VNPI) [17].
In 2002, the University of Southern California updated the VNPI,
including the age parameter. Only in 2008, the National Compre-
hensive Care Network (NCCN) published recommendation on
treatment of DCIS presenting surgery alone as an acceptable
alternative to excision plus radiation therapy [18]. The NCCN study
also presented factors that may affect the rate of local recurrence
for DCIS: symptomatic patients for the presence of a palpable mass,
tumor size, presence of necrosis, margins width and age younger
than 50 years.
Our study examined the effect of surgery alone on local recur-
rence rates in women affected by DCIS low-risk subtypes.
2. Material and methods
We reviewed our prospectively-maintained database collecting
all patients treated for breast cancer from 1998 to 2013 and selected
all patients affected by DCIS treated with excision alone because of
patients' personal choice not shared by our oncologists. We divided
our population in two groups: the ﬁrst one included all patients
with pure ductal carcinoma in situ (no microinvasion), tumor size
smaller than 20mm, nuclear grade 1 or 2, margin not involved after
surgery, not palpable mass and age of 65 or older; the second group
included all patients affected by DCIS who did not undergo RT
therapy not presenting the abovementioned criteria. No systemic
or radiation therapy was used in conjunction with surgery for any
patient in the two groups.
3. Statistical analysis
Values are expressed as mean ± standard deviation when
indicated. A p value of 0.05 or less was considered statistically
signiﬁcant. KaplaneMeier analysis was used to determine local
recurrence. Statistical analyses were performed using SPSS 20
software package (SPSS, Inc, Chicago, IL).
4. Results
A total of 916 patients with the diagnosis of DCIS were identi-
ﬁed. 44 patients have been treated with surgery alone. 24 patients
presented our inclusion criteria and represented our group 1. Ten
patients received surgery alone while 14 received tamoxifen as
adjuvant hormonal therapy in group 1. All patients in group 2
received adjuvant hormonal therapy. No patients in both groups
underwent systemic therapy. Mean age was 68,6 years (range
65e80) for the ﬁrst group and 62 years (range 48e74) for the
second group. The median time of follow-up was 66,3 months
(range 11e137) for the ﬁrst group and 74months (range 14e151) for
the second group. The median size of disease was 8 ± 2.6 mm and
17 ± 4.7 mm for the ﬁrst and the second group respectively.
No local recurrences have been described in the ﬁrst group. No
patients presented distant metastases while 4 patients died for
other causes (1 liver failure, 1 renal insufﬁciency, 1 lung cancer, 1
pulmonary emphysema).We observed 5 local recurrences (2 DCIS and 3 DCI) in the sec-
ond group with a local recurrence rate of 25%, signiﬁcantly higher
when compared with the ﬁrst group (p < 0.05) (Fig. 1).5. Discussion
DCIS is a common non-life-threatening breast cancer, usually
asymptomatic and diagnosed through mammographic screening
programs. The management of DCIS includes mastectomy or
lumpectomy followed by radiation therapy. Although many pro-
spective randomized clinical trials prove that the use of RT reduces
the risk of a local recurrence in the ipsilateral breast by at least 50%
[19e21], other reports show excellent survival rates in DCIS treated
without RT. According to this evidence, many authors argued about
the possibility of avoiding RT in certain subsets of women affected
by DCIS [14,22e36]. The NSABP B-17 trial was the ﬁrst randomized,
controlled trial treating DCIS patients with lumpectomy only [19]. It
revealed a 15-year ipsilateral breast recurrence rate of 35% and
19,8% respectively without and with adjuvant RT. Lagios [23,24]
presented local recurrence rates decreasing to 9% at 12 years of
follow-up selecting low grade DCIS, smaller size (<25 mm) and
1 mm or more of free margins. In 2002 Silverstein [22] reported a
local recurrence rate of 6% at 12 years of follow-up adding as a
further criteria the age of 50 or older. In our study we respect all the
inclusion criteria of the USC/VNPI and NCCN [18], furtherly focusing
our attention on patient older than 65, obtaining no local re-
currences at a median follow-up of 66,3 months. 4 patients in our
second group not meeting two of our inclusion criteria developed a
local recurrence in the follow-up. On the other side the possibility
of avoiding RT improve patients quality of life, particularly in the
elderly.6. Conclusion
Our study proves that the risk of a local recurrence for DCIS
varies by age, grade, size, palpable or no palpable mass and margin
status after surgery. Despite the small number of patients and the
short follow-up of our study, our ﬁndings can be used to guide
oncologists and radiotherapists in their treatment decisions for
G. Falco et al. / International Journal of Surgery 12 (2014) S47eS49 S49womenwith DCIS.Whole breast RT remains the standard of care for
the treatment of DCIS in all patients not presenting all the criteria
considered in our study. More information is needed to understand
the role of an hormonal therapy with tamoxifen when RT is not
given.
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